NASDAQ:AQXP Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free AQXP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$29.88▼$31.5250-Day Range$3.68▼$4.0352-Week Range$2.00▼$3.84Volume47,839 shsAverage Volume239,362 shsMarket Capitalization$705.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Aquinox Pharmaceuticals alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.Read More Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. AQXP Stock News HeadlinesFebruary 11, 2024 | finance.yahoo.comMirum Pharmaceuticals, Inc. (MIRM)September 24, 2023 | finance.yahoo.comWhy Aquinox Pharma (AQXP) Stock Might be a Great PickApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.July 26, 2023 | thestreet.comAquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings BeatJune 9, 2022 | seekingalpha.comAquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%See More Headlines Receive AQXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AQXP CUSIPN/A CIK1404644 Webwww.aqxpharma.com Phone604-629-9223FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.13% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17 Sales & Book Value Annual Sales$25 million Price / Sales28.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book9.70Miscellaneous Outstanding Shares23,540,000Free FloatN/AMarket Cap$705.26 million OptionableNot Optionable Beta-7.37 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. David J. Main (Age 54)Co-Founder, Chairman, CEO & Pres Mr. Kamran Alam (Age 45)CFO, VP of Fin. & Corp. Sec. Ms. Shelley McCloskey (Age 59)VP of HR & Admin. Key CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHLongboard PharmaceuticalsNASDAQ:LBPHOcular TherapeutixNASDAQ:OCULArcturus TherapeuticsNASDAQ:ARCTPliant TherapeuticsNASDAQ:PLRXView All Competitors AQXP Stock Analysis - Frequently Asked Questions How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43. What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY), Inovio Pharmaceuticals (INO), SodaStream International (SODA) and ZIOPHARM Oncology (ZIOP). This page (NASDAQ:AQXP) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHis win rate puts Warren Buffett to shame… Investing DailyThe A.I. story nobody is telling you (Read ASAP)TradeSmithEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
